Pasteur dengue vaccine not 100% but encourages competition
This article was originally published in Scrip
Executive Summary
When Sanofi Pasteur announced in July 2012 that its recombinant dengue fever vaccine CYD-TDV had completed a Phase II study in Thailand, it came as somewhat of a surprise that the efficacy of the vaccine did not approach 100%. With the publication of the results from that trial in the 11 September issue of The Lancet, it is now clear the fly in the ointment is primarily the vaccine's lack of efficacy against the DENV2 subtype of dengue, one of four virus serotypes against which the vaccine was designed.